Sign in Subscribe

Archive

A collection of 943 issues

Latest

Lynch syndrome surveillance review highlights quality standards and emerging AI tools

Skip to content The CRC Digest Lynch syndrome surveillance review highlights quality standards and emerging AI tools A review in Family Cancer examines gene-specific cancer risk, colonoscopy quality metrics, and complementary strategies including fecal immunochemical testing for Lynch syndrome surveillance, noting that randomized trials showed no clear benefit from computer-aided

Metastasis resection after biomarker-guided chemotherapy extends survival to 61 months

Skip to content The CRC Digest ▸ TREATMENT Metastasis resection after biomarker-guided chemotherapy extends survival to 61 months In the IVOPAK II study, patients with initially nonresectable metastatic colorectal cancer who underwent secondary metastasis resection after biomarker-stratified first-line treatment had a median overall survival of 61 months versus 22 months for

Phase II trial tests anti-EGFR rechallenge in ctDNA-selected metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Phase II trial tests anti-EGFR rechallenge in ctDNA-selected metastatic CRC The ROMANCE trial is randomizing 150 patients with circulating tumor DNA-negative hyperselected metastatic colorectal cancer to irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab as third-line therapy, aiming to improve objective response

Mailed FIT outreach raises screening rates to 39% in underserved populations after three years

Skip to content The CRC Digest ▪ SCREENING Mailed FIT outreach raises screening rates to 39% in underserved populations after three years A randomized trial across 16 community health clinics found that annual mailed fecal immunochemical test kits with educational materials and phone reminders increased screening uptake to 39.4% at

FDA converts pembrolizumab approval for TMB-high tumors, raises threshold to ≥13 mutations/megabase

Skip to content The CRC Digest ● REGULATORY FDA converts pembrolizumab approval for TMB-high tumors, raises threshold to ≥13 mutations/megabase The FDA granted traditional approval for pembrolizumab in unresectable or metastatic TMB-high solid tumors, updating the definition from ≥10 to ≥13 mutations/megabase after efficacy was not confirmed in the

CRC Research Update — October 22, 2026

Today's colorectal cancer research highlights

Immunotherapy resistance in dMMR colorectal cancer follows evolutionary trajectory

Skip to content The CRC Digest Immunotherapy resistance in dMMR colorectal cancer follows evolutionary trajectory A review proposes that resistance evolves from early immune evasion through adaptive immunosuppression to advanced metastatic resistance with spatial heterogeneity. (Crit Rev Oncol Hematol) This content is informational only and does not constitute medical advice.

Anti-IL-1α antibody vilamakitug meets primary endpoint in refractory metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Anti-IL-1α antibody vilamakitug meets primary endpoint in refractory metastatic colorectal cancer In the phase 2 TASKIN trial, 61.3% of patients receiving vilamakitug plus standard-of-care therapy were alive at 12 months compared with 55.7% in the control arm, meeting the prespecified efficacy

Oral trifluridine/tipiracil plus EGFR antibodies shows promise for frail patients with RAS wild-type mCRC

Skip to content The CRC Digest ▸ TREATMENT Oral trifluridine/tipiracil plus EGFR antibodies shows promise for frail patients with RAS wild-type mCRC A systematic review found that in third-line and beyond, the combination of trifluridine/tipiracil with cetuximab or panitumumab showed median progression-free survival ranging from 2.4 to 5.

Maintenance immunotherapy after complete response may not be necessary in dMMR/MSI-H rectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Maintenance immunotherapy after complete response may not be necessary in dMMR/MSI-H rectal cancer A multicenter cohort study of 129 patients who entered non-operative management after achieving clinical complete response with PD-1 inhibitors found 3-year disease-free survival was 96.2% with observation